Wellspect, a leading name in the medical technology industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2014, the company has quickly established itself as a pioneer in innovative healthcare solutions, particularly in the fields of urology and continence care. Wellspect is renowned for its core products, including the LoFric range of intermittent catheters, which are distinguished by their unique hydrophilic coating that enhances comfort and reduces the risk of urinary tract infections. The company’s commitment to quality and patient-centric design has positioned it as a trusted partner in healthcare, achieving notable recognition for its contributions to improving patient outcomes. With a focus on research and development, Wellspect continues to lead the way in advancing medical technologies that empower individuals to manage their health with confidence.
How does Wellspect's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Wellspect's score of 55 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Wellspect AB reported total greenhouse gas emissions of approximately 25,442,000 kg CO2e for Scope 1, 154,000 kg CO2e for Scope 2, and about 22,500,000 kg CO2e for Scope 3 emissions. The Scope 3 emissions included significant contributions from purchased goods and services (approximately 133,554,000 kg CO2e) and upstream transportation and distribution (about 39,474,000 kg CO2e). Wellspect has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 80% by 2030 from a 2021 baseline. Additionally, they plan to cut Scope 3 emissions, specifically in upstream transportation and distribution, waste generated in operations, and upstream leased assets, by 42% within the same timeframe. Long-term goals include a 95% reduction in Scope 1 and 2 emissions and a 90% reduction in total Scope 3 emissions by 2045. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Wellspect's commitment to achieving net-zero GHG emissions across its value chain by 2045. The company is a current subsidiary of Wellspect HealthCare AB, which provides the emissions data and climate initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 23,931,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 1,295,000 | 000,000 | 000,000 |
| Scope 3 | 19,783,000 | 00,000,000 | 00,000,000 |
Wellspect's Scope 3 emissions, which increased by 7% last year and increased by approximately 14% since 2021, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 47% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 594% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Wellspect has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Common questions about Wellspect's sustainability data and climate commitments